Search results for "RITU"

showing 10 items of 1485 documents

Interactive effects of aging and aerobic capacity on energy metabolism-related metabolites of serum, skeletal muscle, and white adipose tissue

2021

ABSTRACTAerobic capacity is a strong predictor of longevity. With aging, aerobic capacity decreases concomitantly with changes in whole body metabolism leading to increased disease risk. To address the role of aerobic capacity, aging and their interaction on metabolism, we utilized rat models of low and high intrinsic aerobic capacity (LCRs/HCRs) and assessed the metabolomics of serum, muscle, and white adipose tissue (WAT). We compared LCRs and HCRs at two time points: Young rats were sacrificed at 9 months, and old rats were sacrificed at 21 months. Targeted and semi-quantitative metabolomics analysis was performed on ultra-pressure Liquid Chromatography Tandem Mass Spectrometry (UPLC-MS)…

0301 basic medicineAgingWhite adipose tissue030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicineTandem Mass SpectrometryMetabolitesaineenvaihduntametabolitesALL-CAUSE MORTALITY2. Zero hungerchemistry.chemical_classification0303 health sciencesmetabolomicsAmino acidmedicine.anatomical_structureCARDIOVASCULAR-DISEASEOBESITYaerobinen suorituskykyOriginal ArticleCARDIORESPIRATORY FITNESSARTIFICIAL SELECTIONmedicine.medical_specialtyAdipose Tissue WhiteEXERCISErasva-aineenvaihdunta03 medical and health sciencesMetabolomicsFATNESSAerobic capacityInternal medicinemedicineAnimalsMetabolomicsBeta (finance)Muscle SkeletalAerobic capacity030304 developmental biologyAMINO-ACID-METABOLISMFatty acid metabolismagingSkeletal muscleLipid metabolismCardiorespiratory fitnessMetabolismRatsaerobic capacityikääntyminen030104 developmental biologyEndocrinologyPHYSICAL-ACTIVITYchemistryFUEL SELECTIONaineenvaihduntatuotteet3111 Biomedicinekoe-eläinmallitGeriatrics and GerontologyEnergy MetabolismChromatography Liquid
researchProduct

Checkpoint Inhibition in Non-Hodgkin's Lymphoma.

2017

As patients continue to die from malignant lymphoma, novel treatment options continue to be warranted. To successfully grow and spread, tumor cells need to escape the immune system; therefore, the augmentation or restoration of immune effectors against the malignant cell could be of great value, as shown, e.g., for allogeneic transplantation. A deepened understanding of the regulation of activation and inhibition of the T cell-based effector mechanisms has led to the development of drugs that are able to modify specific checkpoints of this system and thereby raise an immune response against tumor cells. With dramatic responses observed in Hodgkin's disease (HD), interest has risen to explor…

0301 basic medicineCancer ResearchAllogeneic transplantationT cellT-LymphocytesAntineoplastic AgentsDisease03 medical and health sciences0302 clinical medicineImmune systemhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineEffectorbusiness.industryLymphoma Non-HodgkinAntibodies MonoclonalHematologymedicine.diseaseIpilimumabLymphomaNon-Hodgkin's lymphoma030104 developmental biologymedicine.anatomical_structureNivolumabOncology030220 oncology & carcinogenesisCancer researchTumor EscapePrimary mediastinal B-cell lymphomabusinessRituximabOncology research and treatment
researchProduct

Interleukin-25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine Sjögren's Syndrome

2018

Objective To investigate the role of the interleukin-25 (IL-25)/IL-17 receptor B (IL-17RB) axis in experimental Sjogren's syndrome (SS) and in patients with primary SS and primary SS-associated lymphoma. Methods Expression of IL-25, IL-17RB, IL-17B, and tumor necrosis factor receptor-associated factor 6 (TRAF6) was analyzed on minor salivary gland (SG) samples from patients with primary SS and on parotid gland samples from patients with primary SS-associated B cell non-Hodgkin's lymphoma (NHL). IL-17RB expression and the frequencies of natural group 2 innate lymphoid cells (ILC2s), inflammatory ILC2s, and M2-polarized macrophages were assessed by flow cytometry in SG mononuclear cells and p…

0301 basic medicineMaleLymphomaMacrophageImmunologyPeripheral blood mononuclear cellSalivary GlandSalivary GlandsFlow cytometry03 medical and health sciencesMice0302 clinical medicineRheumatologyInterleukin 25AnimalsHumansMedicineImmunology and AllergyLymphocytesB cellAgedReceptors Interleukin-17medicine.diagnostic_testbusiness.industryAnimalMacrophagesInnate lymphoid cellInterleukin-17Middle Agedmedicine.diseaseImmunity InnateLymphomaSettore MED/16 - Reumatologia030104 developmental biologymedicine.anatomical_structureSjogren's SyndromeImmunologyImmunology and Allergy; Rheumatology; ImmunologyLeukocytes MononuclearRituximabTumor necrosis factor alphaFemaleLymphocytebusiness030215 immunologymedicine.drugHuman
researchProduct

Intrinsic aerobic capacity governs the associations between gut microbiota composition and fat metabolism age-dependently in rat siblings

2017

Host genetic factors affecting the gut microbiome play an important role in obesity, yet limited attention has been paid on the host genetic factors linked to physical fitness in modifying the microbiome. This study determined whether sibling-matched pairs of rats selectively bred for high (HCR) and low (LCR) aerobic capacity differ in their microbiome age-dependently and which taxa associate with differential in metabolism. Several taxa in young adult rats (hereafter young) linked to inherited aerobic capacity, while in older adult (hereafter old) rats most of the differences between the lines associated with body weight. Despite the absence of weight differential between LCR and HCR when…

0301 basic medicineMalePhysiologyPhysical fitnessGut floraVeillonellaceaeRuminococcusgeeniekspressioaineenvaihduntarasva-arvot2. Zero hungerGeneticsintestinesExercise Toleranceta3141Actinobacteriaaerobinen suorituskykyFemaleResearch ArticleBiologyta3111rasva-aineenvaihdunta03 medical and health sciencesProteobacteriaGeneticsmedicinefatty acid levelsAnimalsAerobic capacitygut microbiotabusiness.industryHost (biology)ta1184Lipid metabolismmedicine.diseasebiology.organism_classificationLipid MetabolismObesityGut microbiomeGastrointestinal MicrobiomeRatsaerobic capacitymikrobisto030104 developmental biologysuolistoPhysical Fitnessgene expressionbusinessmetabolismhuman activities
researchProduct

How do microbial communities in top-and subsoil respond to root litter addition under field conditions?

2016

Abstract Contrasting microbial community composition and activity at different soil depths may affect root litter decomposition. These effects have up to now been investigated mainly in laboratory studies, which may not be able to take into account complex in situ conditions. Our study aimed to analyze the composition and activity of microbial communities after addition of 13 C labeled wheat root litter to a loamy soil under grassland at 30, 60 and 90 cm depths, during a three-year field experiment. We investigated the dynamics of bacterial and fungal abundances and community structures by DNA genotyping and pyrosequencing of 16S and 18S rDNAs. The genetic structures of bacterial and fungal…

0301 basic medicineMicroorganism[SDV]Life Sciences [q-bio]Soil ScienceBiologyMicrobiology03 medical and health sciencesBotanyExtra-cellular enzyme activitiesOrganic matterTop-and subsoilSubsoilWheat root2. Zero hungerchemistry.chemical_classificationDetritusCommunity04 agricultural and veterinary sciences15. Life on landPlant litter030104 developmental biologychemistryMicrobial population biology040103 agronomy & agricultureLitter0401 agriculture forestry and fisheries
researchProduct

SAFETY AND CLINICAL ACTIVITY OF TEMSIROLIMUS IN COMBINATION WITH RITUXIMAB AND DHAP IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMP…

2017

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryHematologyGeneral MedicineTemsirolimus03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineDHAPmedicineRefractory Diffuse Large B-Cell LymphomaIn patientRituximabbusinessmedicine.drugHematological Oncology
researchProduct

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers

2016

// Giulia Bon 1, * , Rossella Loria 1, * , Carla Azzurra Amoreo 2 , Alessandra Verdina 1 , Isabella Sperduti 2 , Arianna Mastrofrancesco 3 , Silvia Soddu 1 , Maria Grazia Diodoro 2 , Marcella Mottolese 2 , Matilde Todaro 4 , Giorgio Stassi 4 , Michele Milella 5 , Ruggero De Maria 6 , Rita Falcioni 1 1 Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy 2 Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy 3 Physiopathology Laboratory of Skin, IRCCS San Gallicano Dermatological Institute, Rome, Italy 4 Surgical and Oncological Scien…

0301 basic medicineOncologyMAPK/ERK pathwaymedicine.medical_specialtyPatritumabColorectal cancerHER3; MAPK; PI3K; colon cancers; drug resistanceDrug resistancePI3K03 medical and health sciencesSettore MED/04 - PATOLOGIA GENERALEcolon cancersHER3Internal medicinemedicineColon cancers; Drug resistance; HER3; MAPK; PI3K; Oncologyskin and connective tissue diseasesPI3K/AKT/mTOR pathwayTrametinibSettore MED/06 - ONCOLOGIA MEDICAdrug resistancebusiness.industryCancermedicine.diseaseMAPKbody regionsClinical trial030104 developmental biologyOncologycolon cancerbusinessResearch Paper
researchProduct

Gender medicine and oncology: report and consensus of an ESMO workshop.

2019

Background: The importance of sex and gender as modulators of disease biology and treatment outcomes is well known in other disciplines of medicine, such as cardiology, but remains an undervalued issue in oncology. Considering the increasing evidence for their relevance, European Society for Medical Oncology decided to address this topic and organized a multidisciplinary workshop in Lausanne, Switzerland, on 30 November and 1 December 2018.

0301 basic medicineOncologyMalemedicine.medical_specialtypopulation pharmacokinetic analysissuperior survivalDecision MakingMEDLINElymphomaDiseaseclearanceMedical Oncology03 medical and health sciences0302 clinical medicinerituximabInternal medicineNeoplasmsPhysiciansEpidemiologymedicinegendermelanomasexcancerHumansDosingfemale-patientsSex Characteristicsbusiness.industrygender medicineCancerHematologymedicine.diseaseChemotherapy regimenClinical trial030104 developmental biologyTreatment Outcome030220 oncology & carcinogenesisoncologyimpactBody CompositionFemalepharmacologybusinesssex-differencesSex characteristicsAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (D…

2017

TPS7571 Background: Patients ineligible for stem cell transplantation (SCT) or who relapse after SCT, and those who fail to respond to second-line or salvage chemotherapy, represent an unmet medical need for which new therapeutic strategies are required. MOR208 is a novel Fc-enhanced, humanized, monoclonal antibody directed against CD19. Significant single-agent activity of MOR208 in patients with R-R DLBCL (Jurczak et al., J Clin Oncol 34, 2016 [suppl; abstr 7545]) and enhancement of MOR208-mediated cytotoxicity by BEN in preclinical studies, provide a strong rationale to study MOR208 + BEN in patients with R-R DLBCL. Methods: B-MIND is a randomized (1:1), two-arm, multicenter, open-label…

0301 basic medicinePHASE II/III TRIALOncologyBendamustineCancer Researchmedicine.medical_specialtybusiness.industrymedicine.diseaseSurgeryTransplantation03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyRefractory030220 oncology & carcinogenesisInternal medicinemedicineRituximabIn patientStem cellbusinessDiffuse large B-cell lymphomamedicine.drugJournal of Clinical Oncology
researchProduct

Incidence, Diagnosis, and Outcome of Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Nationwide Survey By the Spanish Apheresis Group

2019

Introduction: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare disease characterized by a severe deficiency of the enzymatic activity of ADAMTS13 caused by autoantibodies, with an incidence of 3-4 x106inhabitants per year according to the few published data available. Accurate estimates of the incidence of aTTP are important to assess the resources required for current treatments and to anticipate the need to develop new treatments. The aim of this study was to determine the actualincidence of aTTP in Spain, as well as its diagnosis, management, and associated complications. Material and methods:A cross-sectional surveywascarried out among hematologists working in Spanish hospi…

0301 basic medicinePediatricsmedicine.medical_specialtyExacerbationImmunologyPopulationThrombotic thrombocytopenic purpuraBiochemistrylaw.invention03 medical and health sciences0302 clinical medicineInterquartile rangelawmedicineeducationeducation.field_of_studybusiness.industryIncidence (epidemiology)Mortality rateCell BiologyHematologymedicine.diseaseIntensive care unit030104 developmental biologyRituximabbusiness030215 immunologymedicine.drugBlood
researchProduct